Glycosyloxazoline: a key building block in the chemoenzymatic synthesis of glycoproteins 904285-94-5

Glycosyloxazolines are a type of active sugar donor molecules with unique cyclic structures, playing a crucial role in modern glycobiology and glycoprotein drug development. As a core reagent for the chemoenzymatic synthesis of uniform glycoproteins, it provides a powerful tool for exploring the function of sugar chains and developing the next generation of biological therapies.

Chemical Information

Chemical name: Glycan Oxazoline (No. CBNGO00036)

Common name: Glycosyloxazoline

Chemical formula: C38H63NO30

Molecular weight: 1013.90 g/mol

CAS number: 904285-94-5

Structural features

The structural design of glycosyloxazoline is exquisite and its unique features are:

Stable cyclic active intermediate: The molecule protects and activates the anomeric carbon of the sugar group through the 1,2-oxazoline ring structure. This cyclic structure is formed by C1 and the N-acetylamino group at the 2-position of the glycosyl group, and is a high-energy intermediate with moderate energy.

Ideal substrate for specific enzymatic reactions: This structure enables it to be efficiently recognized and utilized by endo-β-N-acetylglucosaminidase (ENGase) and its modified mutants (such as Endo-S, Endo-M mutants). Through the transition state stabilization mechanism, the enzyme specifically cleaves the C-O bond of the oxazoline ring, and efficiently and specifically transfers the entire sugar chain to the specific asparagine (Asn) of the target protein or peptide chain, forming a natural β-1,4-glycosidic bond.

Main applications and advantages

Chemoenzymatic synthesis of homogeneous glycoproteins

It is difficult to prepare recombinant glycoproteins with clear and uniform structures using traditional methods. The glycosyloxazoline strategy achieves a breakthrough through "sugar chain engineering":

Efficient and precise glycosylation: Utilizing the transglycosylation activity of endoglycosidase and using glycosyloxazoline as the donor, the core fucosylated or afucosylated antibody Fc segment, or other glycoproteins/polypeptides can be directly reshaped or de novo synthesized. This process has excellent regio- and stereoselectivity, clear product structure, and high yield.

Obtain natural and accurate glycoforms: This approach can transfer complete natural sugar chains such as complex, hybrid or high-mannose sugar chains to proteins as a whole, avoiding the cumbersome protection and deprotection steps in chemical synthesis, and maintaining the original structure and biological activity of sugar chains to the maximum extent.

Antibody functionalization and drug conjugation (ADC) development

Glycosylation directly affects the effector function, half-life, and immunogenicity of antibodies.

Antibody function optimization: By using oxazoline donors with different sugar chain structures, the glycosylation pattern of the antibody can be precisely controlled, thereby systematically studying the impact of specific glycoforms (such as defucosylation to enhance ADCC effects, or sialylation to modulate anti-inflammatory activity) on drug function, and designing and optimizing treatment plans accordingly.

New approach to site-directed conjugation: The glycosylation site (Asn297) provides a natural, highly conserved site-directed modification site for antibody-drug conjugation. By engineering the introduced sugar chains or utilizing specific reactive groups generated after glycosylation remodeling, functional molecules such as toxins and fluorescent probes can be loaded at fixed points and uniformly, which will help develop a new generation of ADC drugs with better efficacy and fewer side effects.

Basic glycoscience and diagnostic tool development

Study on the structure and function of glycoproteins: Glycosyloxazoline is an essential tool for the preparation of serialized glycoprotein standards with well-defined structures. These standards are indispensable for in-depth study of the specific mechanisms of sugar chains in protein folding, stability, receptor recognition, and cell signal transduction.

Novel enzyme inhibitors and probe design: Its characteristics as a transition state analogue of glycoside hydrolase/transferase reaction make it an ideal template for the design of potent inhibitors against this type of enzyme, and also provides ideas for the development of molecular probes and diagnostic tools related to the glycosylation process.

Conclusion

Glycosyloxazolines represent an advanced strategy in the field of glycoscience that combines the wisdom of chemical synthesis and enzymatic catalysis. It breaks through the bottleneck of difficult uniform preparation of complex glycoproteins, not only provides precise molecular tools for basic research, but also promotes the development of next-generation biotherapeutics with glycoengineering as the core, such as optimized antibodies, new ADCs and customized glycoprotein therapies, showing broad prospects for translational medicine.

The above information is provided by the editor of KASONS and is for scientific research only.